Nuveen
LUCD icon

Nuveen’s Lucid Diagnostics LUCD Stock Holding History

Nuveen’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
195,065
+104,831
+116% +$113K ﹤0.01% 3630
2026
Q1 		$104K Hold
90,234
– – ﹤0.01% 3175
2025
Q4 		$98.4K Hold
90,234
– – ﹤0.01% 3213
2025
Q3 		$91.1K Sell
90,234
-153,040
-63% -$167K ﹤0.01% 3229
2025
Q2 		$280K Buy
+243,274
New +$314K ﹤0.01% 3083

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Nuveen's LUCD Position: Q2 2026 in Review

Nuveen increased its Lucid Diagnostics (LUCD) stake by 116% in Q2 2026, buying an estimated $113K and bringing the position to 195,065 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #3630.

Nuveen first reported a position in LUCD in Q2 2025 and has held it in 5 quarters since. The position peaked at $280K in Q2 2025. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Nuveen held 195,065 shares of Lucid Diagnostics worth $209K as of Q2 2026.
  • Nuveen bought 104,831 Lucid Diagnostics shares in Q2 2026, an estimated $113K.
  • Lucid Diagnostics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3630 holding.
  • Nuveen first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • Nuveen's Lucid Diagnostics position peaked at $280K in Q2 2025.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.